• Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=23321251).
  

PubMed=17761288; DOI=10.1016/j.exphem.2007.05.022
Ditzel Santos D., Ho A.W., Tournilhac O., Hatjiharissi E., Leleu X., Xu L., Tassone P., Neri P., Hunter Z.R., Chemaly M.A.Z., Branagan A.R., Manning R.J., Patterson C.J., Moreau A.-S., Ciccarelli B., Adamia S., Kriangkum J., Kutok J.L., Tai Y.-T., Zhang J.-W., Pilarski L.M., Anderson K.C., Munshi N.C., Treon S.P.
Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
Exp. Hematol. 35:1366-1375(2007)

PubMed=18650470; DOI=10.1182/blood-2008-05-154831
Bergsagel P.L., Kuehl W.M.
WSU-WM and BCWM.1 should not be assumed to represent Waldenstrom macroglobulinemia cell lines.
Blood 112:917-917(2008)

PubMed=22950966; DOI=10.3109/10428194.2012.727418
Drexler H.G., Chen S., MacLeod R.A.F.
Would the real Waldenstrom cell line please stand up?
Leuk. Lymphoma 54:224-226(2013)

PubMed=23321251; DOI=10.1182/blood-2012-09-454355; PMCID=PMC3596964
Xu L., Hunter Z.R., Yang G., Zhou Y.-S., Cao Y., Liu X., Morra E., Trojani A., Greco A., Arcaini L., Varettoni M., Brown J.R., Tai Y.-T., Anderson K.C., Munshi N.C., Patterson C.J., Manning R.J., Tripsas C.K., Lindeman N.I., Treon S.P.
MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
Blood 121:2051-2058(2013)

PubMed=25382610; DOI=10.1038/bcj.2014.74; PMCID=PMC5424099
Chitta K.S., Paulus A., Caulfield T.R., Akhtar S., Blake M.K.K., Ailawadhi S., Knight J., Heckman M.G., Pinkerton A.B., Chanan-Khan A.A.
Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenstroms macroglobulinemia.
Blood Cancer J. 4:e260.1-e260.10(2014)

PubMed=25853860; DOI=10.1371/journal.pone.0122338; PMCID=PMC4390194
Paulus A., Chitta K.S., Wallace P.K., Advani P.P., Akhtar S., Blake M.K.K., Ailawadhi S., Chanan-Khan A.A.
Immunophenotyping of Waldenstroms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.
PLoS ONE 10:e0122338.1-e0122338.17(2015)

PubMed=28548645; DOI=10.1038/bcj.2017.40; PMCID=PMC5518884
Paulus A., Akhtar S., Yousaf H.M., Manna A., Paulus S.M., Bashir Y., Caulfield T.R., Blake M.K.K., Chitta K.S., Wang X., Asmann Y., Hudec R., Springer W., Ailawadhi S., Chanan-Khan A.A.
Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.
Blood Cancer J. 7:e565.1-e565.11(2017)